Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 269

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 269
---
 (the “Fresenius Supply Agreement”), pursuant to which Cara retained the right to make and have made KORSUVA (difelikefalin) injection worldwide (excluding the United States, Japan and South Korea) (the “Territory”) for commercial sale by Vifor Fresenius Medical Care Renal Pharma Ltd. in or outside the Territory, and for supply of KORSUVA (difelikefalin) injection to Vifor Fresenius Medical Care Renal Pharma Ltd. The supply price was Cara’s COGS, as calculated under U.S. GAAP, plus an agreed upon margin. Vifor Fresenius Medical Care Renal Pharma Ltd. paid Cara $0 pursuant to the Fresenius Supply Agreement for each of the fiscal years ended December 31, 2024 and 2023. In addition, no amounts were paid to Cara pursuant to the Fresenius Supply Agreement following the fiscal year ended December 31, 2024 through the date the agreement was terminated. The Fresenius Supply Agreement was terminated upon consummation of the Asset Disposition. Asset Purchase Agreement On December 17, 2024, Cara and its subsidiary, Cara Royalty Sub, LLC (“Royalty Sub”, and together with us, each, a “Seller” and together, the “Sellers”), entered into an Asset Purchase Agreement (“APA”) with VFMCRP, pursuant to which, on April 15, 2025, Sellers sold to CSL Vifor and CSL Vifor acquired from Sellers certain assets and rights for the development, manufacture and commercialization of difelikefalin as well as certain associated liabilities (the “Asset Disposition”) for a purchase price of $900,000 (subject to certain adjustments with respect to inventory). Pursuant to the APA, in connection with the consummation of the Asset Disposition, CSL Vifor and HCR (as defined below) entered into a letter agreement with Cara providing that CSL Vifor and HCR would, subject to the satisfaction of conditions to closing under the APA, enter into an amended and restated purchase agreement to amend and replace the existing Purchase and Sale Agreement, dated as of November 1, 2023 (as amended, the “Original HCR Agreement”), by and among Royalty Sub, HCRX Investments HoldCo, L.P. (“HCRX”) and HealthCare Royalty Partners IV, L.P. (“HCR IV” and together with H